Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

26.26 +0.37 (+1.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark ↗
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago. 
Via Investor's Business Daily
News headline image
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 Sexy Small-Cap Stocks to Add Sizzle to Your Portfolio ↗
While small-cap stocks can be incredibly risky, they also offer the potential for dramatic gains you won’t find with the big dogs. 
Via InvestorPlace
News headline image
Assessing Catalyst Pharmaceuticals: Insights From 4 Financial Analysts ↗
 
Via Benzinga
News headline image
Amicus Therapeutics Stock Sees RS Rating Improve To 74 ↗
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday. 
Via Investor's Business Daily
News headline image
Earnings Preview For Catalyst Pharmaceuticals ↗
 
Via Benzinga
News headline image
Why Catalyst Pharmaceuticals Stock Is Trading Lower ↗
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares are trading lower by 13% to $14.89 Friday morning. 
Via Benzinga
News headline image
3 Biopharma Stocks You Don't Want to Miss in the New Bull Market ↗
All three have exciting programs on the way. 
Via The Motley Fool
News headline image
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Top 3 Health Care Stocks You May Want To Dump In Q1 ↗
As of Feb. 29, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
News headline image
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology
Santhera's Study Reports the Results of the 48-Week Treatment with Vamorolone in Patients with Duchenne Muscular Dystrophy (DMD) in the VISION-DMD Study, Supporting the Long-Term Efficacy and Safety... 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
The Company will Host a Conference Call and Webcast on February 29, 2024, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Jim Cramer Likes This Bank 'Very, Very Much,' Says Stock Is Up 7% Over Past 6 Months ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Stanley Black & Decker, Inc. 
Via Benzinga
News headline image
Next Big Thing: 3  Biotech Stocks to Watch for Groundbreaking Advances ↗
With our improving economy, you need to invest in these top biotech stocks that are looking to strike gold this year. 
Via InvestorPlace
Topics Economy
News headline image
3 Biotech Stocks You Can Buy and Hold for the Next Decade ↗
These companies are still in the early innings of their growth potential. 
Via The Motley Fool
News headline image
Forget Shiba Inu: This Stock is Poised for a Potential Bull Run in 2024 ↗
With multiple drugs on the market and revenue ramping up, the sky's the limit. 
Via The Motley Fool
News headline image
Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 Unstoppable S&P 600 Small-Cap Stocks to Buy in January ↗
Small-cap stocks tend to outperform mid- and large-cap stocks over time and make for an important component of a balanced portfolio. 
Via InvestorPlace
Topics Stocks
News headline image
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of Applied Therapeutics, Inc. 
Via Benzinga
News headline image
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
News headline image
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Franklin Covey Shares Fall After Q1 Results, Joins Theravance Biopharma, Voyager Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on Friday. 
Via Benzinga
Topics Stocks
News headline image
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Amgen Stock Sees Relative Strength Rating Improve To 74 ↗
Amgen stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 69 to 74. 
Via Investor's Business Daily
News headline image
Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug Study ↗
On Thursday, Cytokinetics stock cleared a key performance benchmark, with its Relative Strength Rating jumping to 99 from 89 the day before. 
Via Investor's Business Daily
News headline image
Ultragenyx Pharm Stock Hits 80-Plus Relative Strength Rating Benchmark ↗
On Thursday, Ultragenyx Pharm stock received a positive adjustment to its Relative Strength (RS) Rating, from 77 to 81. 
Via Investor's Business Daily
News headline image
Recursion Pharm Showing Market Leadership As Biotech Stocks Shoot Higher ↗
On Tuesday, Recursion Pharm stock reached a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88 the day before. 
Via Investor's Business Daily
News headline image
Small Caps Are On A Tear Including Speculative Biotechs ↗
So far 2023 is going well with our game plan -an end-of-year seasonal rally coupled with a run in speculative biotechs driven by innovation. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.